[Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
Gan To Kagaku Ryoho
; 17(12): 2387-95, 1990 Dec.
Article
en Ja
| MEDLINE
| ID: mdl-2260876
ABSTRACT
Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate), a derivative of cytosine arabinoside, on hematological malignancies was conducted by multi-institutional cooperative group. YNK01 was administered orally at dose of 100-300 mg/body/day for more than 2 weeks. The number of registered and evaluated patients were 211 and 156, respectively. Of 23 patients with acute myelogeneous leukemia (AML), 2 complete response (CR), one partial response (PR) were observed (CR + PR 13.0%). Hypoplastic leukemia (1/4 25%), acute unclassified leukemia (1/1 100%). Of 45 patients with MDS, 2CRs, 6 good response (GR) and 5PRs were observed (CR + PR 28.9%). AML developing after a prior history of MDS (5/17 29.4%), CML-BC (2/9 22.2%). Of 19 patients with CML, 9 achieved CR, 3 achieved PR (63.2%). Of 11 patients with polycythemia vera, 4 achieved CR, 5 achieved PR (81.8%). Of 6 patients with essential thrombocytosis, 2 achieved CR, one achieved PR (50%). The major adverse effects included gastrointestinal toxicities such as nausea, vomiting, anorexia, diarrhea, and elevation of GOT and GPT which were tolerable and reversible. This study indicates that YNK01 is a useful agent against acute leukemia and MDS, especially RAEB, RAEB in T, CMMoL.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Arabinonucleotidos
/
Síndromes Mielodisplásicos
/
Leucemia
/
Citidina Monofosfato
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Asia
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Año:
1990
Tipo del documento:
Article